Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Colorectal Neoplasms

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 61 articles: HTML format

Single Articles

February 2021
1. CHANG GJ
   Primary Tumor Resection in Colorectal Cancer With Synchronous Unresectable Metastasis: Time to End the Debate?
   J Clin Oncol. 2021 Feb 16:JCO2100057. doi: 10.1200/JCO.21.00057.
   PubMed    
   
   
   
2. KANEMITSU Y, Shitara K, Mizusawa J, Hamaguchi T, et al
   Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial.
   J Clin Oncol. 2021 Feb 9:JCO2002447. doi: 10.1200/JCO.20.02447.
   PubMed     Abstract available
   
   
   
3. ENG C
   BRAF Mutation in Colorectal Cancer: An Enigmatic Target.
   J Clin Oncol. 2021;39:259-261.
   PubMed    
   
   
   
4. TABERNERO J, Grothey A, Van Cutsem E, Yaeger R, et al
   Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.
   J Clin Oncol. 2021;39:273-284.
   PubMed     Abstract available
   
   
   January 2021
5. IVESON TJ, Sobrero AF, Yoshino T, Souglakos I, et al
   Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer.
   J Clin Oncol. 2021 Jan 13:JCO2001330. doi: 10.1200/JCO.20.01330.
   PubMed     Abstract available
   
   
   
6. WEISER MR, Hsu M, Bauer PS, Chapman WC Jr, et al
   Clinical Calculator Based on Molecular and Clinicopathologic Characteristics Predicts Recurrence Following Resection of Stage I-III Colon Cancer.
   J Clin Oncol. 2021 Jan 13:JCO2002553. doi: 10.1200/JCO.20.02553.
   PubMed     Abstract available
   
   
   
7. SHI DD, Mamon HJ
   Playing With Dynamite? A Cautious Assessment of TNT.
   J Clin Oncol. 2021;39:103-106.
   PubMed    
   
   
   
8. SCHMOLL HJ, Stein A, Van Cutsem E, Price T, et al
   Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD.
   J Clin Oncol. 2021;39:17-29.
   PubMed     Abstract available
   
   
   December 2020
9. KOPETZ S, Guthrie KA, Morris VK, Lenz HJ, et al
   Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).
   J Clin Oncol. 2020 Dec 23:JCO2001994. doi: 10.1200/JCO.20.01994.
   PubMed     Abstract available
   
   
   
10. COHEN R, Taieb J, Fiskum J, Yothers G, et al
    Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
    J Clin Oncol. 2020 Dec 23:JCO2001600. doi: 10.1200/JCO.20.01600.
    PubMed     Abstract available
    
    
    
11. ZHU J, Liu A, Sun X, Liu L, et al
    Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer.
    J Clin Oncol. 2020;38:4231-4239.
    PubMed     Abstract available
    
    
    
12. BEKELMAN JE, Gupta A, Fishman E, Debono D, et al
    Association Between a National Insurer's Pay-for-Performance Program for Oncology and Changes in Prescribing of Evidence-Based Cancer Drugs and Spending.
    J Clin Oncol. 2020;38:4055-4063.
    PubMed     Abstract available
    
    
    
13. MANNUCCI A, Furniss CS, Ukaegbu C, Horiguchi M, et al
    Comparison of Colorectal and Endometrial Microsatellite Instability Tumor Analysis and Premm5 Risk Assessment for Predicting Pathogenic Germline Variants on Multigene Panel Testing.
    J Clin Oncol. 2020;38:4086-4094.
    PubMed     Abstract available
    
    
    November 2020
14. RAO S
    Reply to S. Kim et al.
    J Clin Oncol. 2020;38:3974-3975.
    PubMed    
    
    
    
15. KIM S, Vernerey D, Borg C
    How to Choose the Right Treatment for Patients With Advanced Squamous Cell Carcinoma in the Absence of a Comparative Randomized Clinical Trial.
    J Clin Oncol. 2020;38:3973-3974.
    PubMed    
    
    
    September 2020
16. TANG W, Ren L, Liu T, Ye Q, et al
    Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial.
    J Clin Oncol. 2020;38:3175-3184.
    PubMed     Abstract available
    
    
    
17. MLECNIK B, Bifulco C, Bindea G, Marliot F, et al
    Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer.
    J Clin Oncol. 2020 Sep 8:JCO1903205. doi: 10.1200/JCO.19.03205.
    PubMed     Abstract available
    
    
    August 2020
18. CREMOLINI C, Antoniotti C, Stein A, Bendell J, et al
    Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer.
    J Clin Oncol. 2020 Aug 20:JCO2001225. doi: 10.1200/JCO.20.01225.
    PubMed     Abstract available
    
    
    
19. RAO S, Sclafani F, Eng C, Adams RA, et al
    International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct.
    J Clin Oncol. 2020;38:2510-2518.
    PubMed     Abstract available
    
    
    April 2020
20. FUKUOKA S, Hara H, Takahashi N, Kojima T, et al
    Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).
    J Clin Oncol. 2020 Apr 28:JCO1903296. doi: 10.1200/JCO.19.03296.
    PubMed     Abstract available
    
    
    March 2020
21. BEEBE-DIMMER JL, Kapron AL, Fraser AM, Smith KR, et al
    Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes.
    J Clin Oncol. 2020 Mar 24:JCO1902808. doi: 10.1200/JCO.19.02808.
    PubMed     Abstract available
    
    
    
22. DELATTRE JF, Cohen R, Henriques J, Falcoz A, et al
    Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR).
    J Clin Oncol. 2020 Mar 13:JCO1901960. doi: 10.1200/JCO.19.01960.
    PubMed     Abstract available
    
    
    January 2020
23. BROWN LC, Armstrong AJ
    Has Mismatch Repair-Deficient Cancer Met Its MATCH?
    J Clin Oncol. 2020;38:183-187.
    PubMed    
    
    
    
24. AZAD NS, Gray RJ, Overman MJ, Schoenfeld JD, et al
    Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study.
    J Clin Oncol. 2020;38:214-222.
    PubMed     Abstract available
    
    
    November 2019
25. LE DT, Kim TW, Van Cutsem E, Geva R, et al
    Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164.
    J Clin Oncol. 2019 Nov 14:JCO1902107. doi: 10.1200/JCO.19.02107.
    PubMed     Abstract available
    
    
    October 2019
26. MODEST DP, Martens UM, Riera-Knorrenschild J, Greeve J, et al
    FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109).
    J Clin Oncol. 2019 Oct 14:JCO1901340. doi: 10.1200/JCO.19.01340.
    PubMed     Abstract available
    
    
    September 2019
27. SUNDAR R, Tan IBH, Chee CE
    Negative Predictive Biomarkers in Colorectal Cancer: PRESSING Ahead.
    J Clin Oncol. 2019 Sep 24:JCO1901977. doi: 10.1200/JCO.19.01977.
    PubMed    
    
    
    
28. MORANO F, Corallo S, Lonardi S, Raimondi A, et al
    Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy.
    J Clin Oncol. 2019 Sep 20:JCO1901254. doi: 10.1200/JCO.19.01254.
    PubMed     Abstract available
    
    
    August 2019
29. GUERCIO BJ, Zhang S, Ou FS, Venook AP, et al
    Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405.
    J Clin Oncol. 2019 Aug 13:JCO1901019. doi: 10.1200/JCO.19.01019.
    PubMed     Abstract available
    
    
    June 2019
30. UENO H, Ishiguro M, Nakatani E, Ishikawa T, et al
    Prospective Multicenter Study on the Prognostic and Predictive Impact of Tumor Budding in Stage II Colon Cancer: Results From the SACURA Trial.
    J Clin Oncol. 2019 Jun 10:JCO1802059. doi: 10.1200/JCO.18.02059.
    PubMed     Abstract available
    
    
    
31. STEBBING J, Singh Wasan H
    Decoding Metastatic Colorectal Cancer to Improve Clinical Decision Making.
    J Clin Oncol. 2019 Jun 7:JCO1901185. doi: 10.1200/JCO.19.01185.
    PubMed    
    
    
    May 2019
32. SMITH TG, Troeschel AN, Castro KM, Arora NK, et al
    Perceptions of Patients With Breast and Colon Cancer of the Management of Cancer-Related Pain, Fatigue, and Emotional Distress in Community Oncology.
    J Clin Oncol. 2019 May 17:JCO1801579. doi: 10.1200/JCO.18.01579.
    PubMed     Abstract available
    
    
    
33. LENZ HJ, Ou FS, Venook AP, Hochster HS, et al
    Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).
    J Clin Oncol. 2019 May 1:JCO1802258. doi: 10.1200/JCO.18.02258.
    PubMed     Abstract available
    
    
    April 2019
34. SALZ T, Lavery JA, Lipitz-Snyderman AN, Boudreau DM, et al
    Trends in Opioid Use Among Older Survivors of Colorectal, Lung, and Breast Cancers.
    J Clin Oncol. 2019;37:1001-1011.
    PubMed     Abstract available
    
    
    
35. LIEU C, Kennedy EB, Bergsland E, Berlin J, et al
    Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline.
    J Clin Oncol. 2019 Apr 15:JCO1900281. doi: 10.1200/JCO.19.00281.
    PubMed     Abstract available
    
    
    March 2019
36. VAN CUTSEM E, Huijberts S, Grothey A, Yaeger R, et al
    Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study.
    J Clin Oncol. 2019 Mar 20:JCO1802459. doi: 10.1200/JCO.18.02459.
    PubMed     Abstract available
    
    
    
37. INNOCENTI F, Ou FS, Qu X, Zemla TJ, et al
    Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome.
    J Clin Oncol. 2019 Mar 13:JCO1801798. doi: 10.1200/JCO.18.01798.
    PubMed     Abstract available
    
    
    
38. SALVADOR MU, Truelson MRF, Mason C, Souders B, et al
    Comprehensive Paired Tumor/Germline Testing for Lynch Syndrome: Bringing Resolution to the Diagnostic Process.
    J Clin Oncol. 2019;37:647-657.
    PubMed     Abstract available
    
    
    February 2019
39. SHUEN AY, Lanni S, Panigrahi GB, Edwards M, et al
    Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic Tissue.
    J Clin Oncol. 2019;37:461-470.
    PubMed     Abstract available
    
    
    
40. ROVITHI M, Gerritse SL, Honeywell RJ, Ten Tije AJ, et al
    Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors.
    J Clin Oncol. 2019;37:411-418.
    PubMed     Abstract available
    
    
    
41. YURGELUN MB, Kastrinos F
    Tumor Testing for Microsatellite Instability to Identify Lynch Syndrome: New Insights Into an Old Diagnostic Strategy.
    J Clin Oncol. 2019;37:263-265.
    PubMed    
    
    
    
42. LATHAM A, Srinivasan P, Kemel Y, Shia J, et al
    Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer.
    J Clin Oncol. 2019;37:286-295.
    PubMed     Abstract available
    
    
    January 2019
43. OGURA A, Konishi T, Cunningham C, Garcia-Aguilar J, et al
    Neoadjuvant (Chemo)radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients With Low cT3/4 Rectal Cancer.
    J Clin Oncol. 2019;37:33-43.
    PubMed     Abstract available
    
    
    November 2018
44. MODEST DP, Fischer von Weikersthal L, Decker T, Vehling-Kaiser U, et al
    Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).
    J Clin Oncol. 2018 Nov 2:JCO1800052. doi: 10.1200/JCO.18.00052.
    PubMed     Abstract available
    
    
    October 2018
45. GUINTER MA, McCullough ML, Gapstur SM, Campbell PT, et al
    Associations of Pre- and Postdiagnosis Diet Quality With Risk of Mortality Among Men and Women With Colorectal Cancer.
    J Clin Oncol. 2018 Oct 19:JCO1800714. doi: 10.1200/JCO.18.00714.
    PubMed     Abstract available
    
    
    September 2018
46. QIN S, Li J, Wang L, Xu J, et al
    Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial.
    J Clin Oncol. 2018 Sep 10:JCO2018783183. doi: 10.1200/JCO.2018.78.3183.
    PubMed     Abstract available
    
    
    June 2018
47. MO M, Yang J, Zhu X, Zhu J, et al
    Bevacizumab Maintenance in Metastatic Colorectal Cancer.
    J Clin Oncol. 2018 Jun 4:JCO2018783795. doi: 10.1200/JCO.2018.78.3795.
    PubMed    
    
    
    May 2018
48. VAN DIJK E, Biesma HD, Cordes M, Smeets D, et al
    Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab.
    J Clin Oncol. 2018 May 24:JCO2017771782. doi: 10.1200/JCO.2017.77.1782.
    PubMed     Abstract available
    
    
    April 2018
49. VENOOK AP
    Advances in Adjuvant Therapy for Colon Cancer: P value or Practical Value.
    J Clin Oncol. 2018 Apr 5:JCO2018778423. doi: 10.1200/JCO.2018.77.8423.
    PubMed    
    
    
    
50. ANDRE T, Vernerey D, Mineur L, Bennouna J, et al
    3 Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.
    J Clin Oncol. 2018 Apr 5:JCO2017760355. doi: 10.1200/JCO.2017.76.0355.
    PubMed     Abstract available
    
    
    
51. SOBRERO A, Lonardi S, Rosati G, Di Bartolomeo M, et al
    FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.
    J Clin Oncol. 2018 Apr 5:JCO2017762187. doi: 10.1200/JCO.2017.76.2187.
    PubMed     Abstract available
    
    
    March 2018
52. SUN R, Horiguchi M, Wei LJ
    Interpreting the Benefit of Trifluridine/Tipiracil in Metastatic Colorectal Cancer With Respect to Progression-Free Survival and Overall Survival.
    J Clin Oncol. 2018 Mar 20:JCO2017775643. doi: 10.1200/JCO.2017.77.5643.
    PubMed    
    
    
    February 2018
53. FADELU T, Zhang S, Niedzwiecki D, Ye X, et al
    Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance).
    J Clin Oncol. 2018 Feb 28:JCO2017755413. doi: 10.1200/JCO.2017.75.5413.
    PubMed     Abstract available
    
    
    January 2018
54. OVERMAN MJ, Lonardi S, Wong KYM, Lenz HJ, et al
    Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.
    J Clin Oncol. 2018 Jan 20:JCO2017769901. doi: 10.1200/JCO.2017.76.9901.
    PubMed     Abstract available
    
    
    
55. APARICIO T, Ghiringhelli F, Boige V, Le Malicot K, et al
    Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9).
    J Clin Oncol. 2018 Jan 18:JCO2017752931. doi: 10.1200/JCO.2017.75.2931.
    PubMed     Abstract available
    
    
    
56. KENZIK KM, Balentine C, Richman J, Kilgore M, et al
    New-Onset Cardiovascular Morbidity in Older Adults With Stage I to III Colorectal Cancer.
    J Clin Oncol. 2018 Jan 16:JCO2017749739. doi: 10.1200/JCO.2017.74.9739.
    PubMed     Abstract available
    
    
    December 2017
57. BUTOW PN, Turner J, Gilchrist J, Sharpe L, et al
    Randomized Trial of ConquerFear: A Novel, Theoretically Based Psychosocial Intervention for Fear of Cancer Recurrence.
    J Clin Oncol. 2017;35:4066-4077.
    PubMed     Abstract available
    
    
    
58. XU J, Kim TW, Shen L, Sriuranpong V, et al
    Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study.
    J Clin Oncol. 2017 Dec 7:JCO2017743245. doi: 10.1200/JCO.2017.74.3245.
    PubMed     Abstract available
    
    
    November 2017
59. COLON-LOPEZ V, Shiels MS, Machin M, Ortiz AP, et al
    Anal Cancer Risk Among People With HIV Infection in the United States.
    J Clin Oncol. 2017 Nov 15:JCO2017749291. doi: 10.1200/JCO.2017.74.9291.
    PubMed     Abstract available
    
    
    
60. WHITNEY RL, Bell JF, Tancredi DJ, Romano PS, et al
    Hospitalization Rates and Predictors of Rehospitalization Among Individuals With Advanced Cancer in the Year After Diagnosis.
    J Clin Oncol. 2017;35:3610-3617.
    PubMed     Abstract available
    
    
    February 2017
61. LOBERG M, Holme O, Kalager M
    Aspirin, Colorectal Cancer, and Cause of Death: A Complex Landscape.
    J Clin Oncol. 2017;35:568-569.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: